179. Profiling Human Neutrophil Functional Responses From Solid-Organ and Stem Cell Transplant Recipients to Candida albicans
Nicolas Barros, MD; Natalie Alexander; Adam Viens; Alex Hopke, PhD; Sally knooshiuhen, MD; Allison Scherer, PhD; Zeina Dagher, PhD; Daniel Irimia, MD, Michael Mansour, MD, PhD; Massachusetts General Hospital, Boston, Massachusetts
Session: 165. Mycology
Friday, October 4, 2019: 12:15 PM

Background. Solid-organ (SOT) and stem cell transplant (SCT) recipients are at increased risk of invasive fungal disease despite normal neutrophil counts in peripheral blood. However, the neutrophils function against fungi has not been completely defined. In this study, we measure human neutrophili anti-candida activity in SOT and SCT recipients.

Methods. SOT and SCT patients were identified and consented from September 2018 until April 2019. Healthy control patients (HC) were identified at primary care clinics. EDTA-anticoagulated peripheral blood was obtained from healthy and transplant patient 2-4 months post-transplant. Neutrophils were isolated by negative selection. C. albicans was incubated for 2 hours with and without human neutrophils at multiplicity of infection (MOI) of 10, 5, and 1. Following neutrophil cell lysis, percent remaining live Candida was measured using a viability dye. In addition, growth inhibition of C. albicans by neutrophil swarming to C. albicans spotted onto glass slide arrays was also assessed by live cell imaging.

Results. 22 SOT (15 kidneys, 7 livers), 20 SCT (allograft) and 22 HC were enrolled. Neutrophils from SOT and SCT had lower C. albicans killing percentages compared with HC at MOI 10 (HC: 47%, SOT: 29%; 24% P = 0.041); MOI 5 (HC: 72%, SOT: 45%; P = 0.001) and MOI 1 (HC: 91%; SOT: 48%; P = 0.001). Neutrophil swarming and fungal control of C. albicans spots was significantly inhibited by neutrophils from SCT when compared with controls (P < 0.0001). Analysis of medications, including tyrosine kinase inhibitor (TKI) use, did not demonstrate significant differences of a specific drug class when patient groups are compared (SCT vs. SOT).

Conclusion. Our study indicates that despite normal circulating numbers, neutrophils from SOT and SCT recipients are dysfunctional and show profoundly impaired anti-Candida activity. There were no medications or laboratory values that predicted functional neutrophil outcome. These data strongly support the use of functional neutrophil profiling to risk stratify those individuals at higher risk for invasive fungal infections.

Disclosures. All authors: No reported disclosures.

1730. Invasive Fusarium Species in Mayo Clinic Patients with Hematologic Malignancies
Courtney Harris, MD; Pritish Tosh, MD; Aaron J. Tande, MD, Mayo Clinic, Rochester, Minnesota
Session: 165. Mycology
Friday, October 4, 2019: 12:15 PM

Background. The epidemiology of fungal infections in hematologic malignancies has changed in the past decade. Triazole prophylaxis has decreased Candida spp infections while infections due to other molds such as Aspergillus and Fusarium have increased. Fusarium has very poor prognosis, and after aspergillosis, is the most common invasive fungal infection in this patient population. We sought to describe fusariosis in patients with hematologic malignancies at the Mayo Clinic.

Methods. We performed a retrospective review of patients with culture-positive Fusarium infection from January 2003 to October 2016 at the Mayo Clinic, Rochester, MN. The records of patients were reviewed for demographics, diagnosis, treatment, and outcomes including mortality. Patients without a diagnosis of hematologic malignancy were excluded. Patients were classified with proven or probable Fusariosis based on the Revised Definitions of Invasive Fungal Disease from the EORTC/MSG Consensus Group.

Results. We identified 14 patients with hematologic malignancies (age range 17–76 years, median age 60 years) with a confirmed culture diagnosis of Fusarium infection classified as proven (9 patients) or probable (5 patients). Two cases were isolated pulmonary infections, 3 extra-pulmonary, and 9 disseminated cases. Two patients had previously undergone stem cell transplantation. Eight patients (57%) were receiving immunosuppression at the time of diagnosis: 2 on voriconazole, 1 on posaconazole, 1 on fluconazole, 3 on echinocandins, and 1 on Amphotericin B. Nine patients (64%) were neutropenic at the time of diagnosis. Amphotericin was the initial treatment in 7 (50%) patients, with voriconazole added for 4 patients for combination therapy the first week. Voriconazole monotherapy was given initially in 5 patients. Seven patients (50%) were deceased at 6 weeks after culture positivity, with an additional 2 patients deceased by 12 weeks.

Conclusion. Fusarium infection outcomes in patients with hematologic malignancies is poor, with neutropenia in more patients than in previous years. Mortality rates were more likely to be disseminated, with high mortality rates. Amphotericin B is commonly used as initial treatment, with many physicians recommending combination therapy with two agents, commonly voriconazole.

Disclosures. All authors: No reported disclosures.

1731. Immune Dysregulation in Mucormycosis
Chhavi Gupta, MBBS, MD; Shakila Das, MBBS; MD; Gargi Rai, MSC; Praveen K. Singh, MSc; Sahaj Dar, PhD; Mohammad A. Ansari, PhD; 1 AIIMS, New Delhi, India; 2 UCMS, Delhi, India; 3 University College of Medical Sciences, Delhi, India; 4 Jazan University, Jizan, Saudi Arabia
Session: 165. Mycology
Friday, October 4, 2019: 12:15 PM

Background. Mucormycosis is a fatal fungal infection with unique predispositions to diabetic patients. Disregulated adaptive immunity contributes to the pathogenesis in all fungal diseases, but activated Th17 cells have laid a new dimension to chronic inflammatory response which was previously attributed to uncontrolled Th1 response. We attempted to study the Th17 and T regulatory (Treg) immune response in diabetic patients with mucormycosis and compared the data with a healthy control and a T2DM case without fungal infection. In addition we could follow-up one patient post 6-month treatment and performed immunological studies.

Methods. 2 ml of blood samples were collected in EDTA vial from two patients who were suffering from diabetes with mucormycosis for immunological investigations. Samples were also taken from age-matched T2DM patient without fungal infection and a healthy volunteer as controls for T-cell parameters. Repeat blood sample was taken to study immune parameters in one patient who was followed up after 6 months. The expression of various T-cell markers was analyzed by immunostaining with the antibodies against CD3, CD4, CD25, CD161, IL-23R (Becton Dickinson (BD) Pharmingen). Fluorescence profiles were analyzed using Flow Jo software (BD Biosciences). The results are expressed as a percentage of positive cells.

Results. The percentages of CD4+ cells were low in both patients when compared with healthy control but it is much higher in diabetes case when compared with others. CD161+ cell population was higher in both patients when compared with healthy control and diabetic patient without fungal infection. The percentage of CD25+ cells was significantly high in patient before treatment when compared with healthy control and diabetics and much lesser than the T2DM group. The percentage of CD25+ was highest in healthy control when compared with others. The profile of CD25+ cells was comparatively similar in patient before treatment and diabetics but we found a higher percentage, in patients after treatment.

Conclusion. The findings in this study indicate the mechanism of immune dysregulation involving Th17 and Treg pathways in mucormycosis and provide evidence that restoration of Th17/Treg may be considered as a therapeutic option for long-term benefit in diabetics.

Disclosures. All authors: No reported disclosures.

1732. A Canine Target Species Challenge Model to Evaluate Efficacy of a Coccidioidomycosis Vaccine
Lisa F. Shubitz, DVM1; Richard Bowen, DVM; Edward J. Robb, DVM2; Daniel A. Powell, PhD3; Angela Bosco-Lauth, DVM4; Arrn Hartwig5; Hien Trinh, DVM6; Mary L. Lewis, Jeffrey A. Peltzinger, PhD7; John N. Galgiani, MD8; University of Arizona College of Medicine, Tucson, Arizona; 9 Anivive Life Sciences, Long Beach, California; 10 University College of Medicine, Arizona, Arizona; 11Avirine Life Sciences, Long Beach, California; 12University College of Medicine, Tucson, Arizona; 13Colorado State University, Fort Collins, Colorado; 14Valley Fever Center for Excellence, Tuscon, Arizona
Session: 165. Mycology
Friday, October 4, 2019: 12:15 PM

Background. The preferred efficacy design for licensing a vaccine for animal use by the Food and Drug Administration (FDA) is the做成 vaccina-challenge design in line with Chapter 9 Code of Federal Regulations, parts 102.5 and 104.5. In this study, we evaluated a Coccidioidomycosis Vaccine in a peridomestic dog challenge model.

Methods. A purposeful challenge model was developed in beagle dogs. To test a cps1, live avirulent canine coccidioidomycosis vaccine, an inhalation disease model was developed in beagle dogs.

Results. Ten of 11 dogs were successfully infected; 5 required early removal at 33 days post 6-month treatment and performed immunological studies.

Conclusion. The preferred efficacy design for licensing a vaccine for animal use by the Food and Drug Administration (FDA) is the vaccine-challenge experimental design in line with Chapter 9 Code of Federal Regulations, parts 102.5 and 104.5. In this study, we evaluated a Coccidioidomycosis Vaccine in a peridomestic dog challenge model.

Disclosures. All authors: No reported disclosures.